In preclinical tumor models, blocking IL6R or gene ablation of intrinsic IL-6 signaling in CTLs, in combination with anti-PD-L1 therapy, enhances the anti-tumor CTL response, and improves tumor control [57]. The gene discussed is IL6R; the disease is neoplasm.